NO20033546D0 - 4-fluor-N-indan-2-yl-benzamid og dets anvendelse som legemiddel - Google Patents

4-fluor-N-indan-2-yl-benzamid og dets anvendelse som legemiddel

Info

Publication number
NO20033546D0
NO20033546D0 NO20033546A NO20033546A NO20033546D0 NO 20033546 D0 NO20033546 D0 NO 20033546D0 NO 20033546 A NO20033546 A NO 20033546A NO 20033546 A NO20033546 A NO 20033546A NO 20033546 D0 NO20033546 D0 NO 20033546D0
Authority
NO
Norway
Prior art keywords
indan
fluoro
benzamide
drug
synthase
Prior art date
Application number
NO20033546A
Other languages
English (en)
Other versions
NO333522B1 (no
NO20033546L (no
Inventor
Paulus Wohlfart
Teri Suzuki
Ramalinga M Dharanipragada
Alena Safarova
Armin Walser
Hartmut Strobel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20033546D0 publication Critical patent/NO20033546D0/no
Publication of NO20033546L publication Critical patent/NO20033546L/no
Publication of NO333522B1 publication Critical patent/NO333522B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
NO20033546A 2001-02-13 2003-08-11 Anvendelse av 4-fluor-N-indan-2-yl-benzamid ved terapeutisk behandling NO333522B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01102852 2001-02-13
PCT/EP2002/001443 WO2002064146A1 (en) 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Publications (3)

Publication Number Publication Date
NO20033546D0 true NO20033546D0 (no) 2003-08-11
NO20033546L NO20033546L (no) 2003-09-24
NO333522B1 NO333522B1 (no) 2013-07-01

Family

ID=8176423

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033546A NO333522B1 (no) 2001-02-13 2003-08-11 Anvendelse av 4-fluor-N-indan-2-yl-benzamid ved terapeutisk behandling

Country Status (34)

Country Link
US (3) US6617359B2 (no)
EP (1) EP1361882B1 (no)
JP (1) JP4317689B2 (no)
KR (1) KR101017531B1 (no)
CN (1) CN100553631C (no)
AT (1) ATE344669T1 (no)
AU (1) AU2002253009B2 (no)
BG (1) BG66065B1 (no)
BR (1) BR0207178A (no)
CA (1) CA2437966C (no)
CY (1) CY1106278T1 (no)
CZ (1) CZ20032154A3 (no)
DE (1) DE60215919T2 (no)
DK (1) DK1361882T3 (no)
EE (1) EE05302B1 (no)
ES (1) ES2274025T3 (no)
HK (1) HK1062140A1 (no)
HR (1) HRP20030646A2 (no)
HU (1) HUP0302845A3 (no)
IL (2) IL157208A0 (no)
MX (1) MXPA03006841A (no)
MY (1) MY135778A (no)
NO (1) NO333522B1 (no)
NZ (1) NZ527469A (no)
PE (1) PE20020884A1 (no)
PL (1) PL363452A1 (no)
PT (1) PT1361882E (no)
RS (1) RS51645B (no)
RU (1) RU2308946C2 (no)
SI (1) SI1361882T1 (no)
SK (1) SK286513B6 (no)
TW (1) TWI241190B (no)
WO (1) WO2002064146A1 (no)
ZA (1) ZA200305412B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020870A1 (es) * 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
ATE430728T1 (de) 2002-10-21 2009-05-15 Janssen Pharmaceutica Nv Substituierte tetraline und indane und ihre verwendung
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
US7132536B2 (en) * 2003-04-24 2006-11-07 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
DE602004011348T2 (de) * 2003-07-03 2009-01-08 Eli Lilly And Co., Indianapolis Indanderivate als muscarinrezeptoragonisten
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
EP1529525A1 (en) * 2003-11-06 2005-05-11 Aventis Pharma Deutschland GmbH ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
EP1708690B1 (en) 2003-11-17 2016-07-20 BioMarin Pharmaceutical Inc. Treatment of phenylketonuria with bh4
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
CA2581814C (en) * 2004-11-17 2015-10-13 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
EP1814553A4 (en) * 2004-11-19 2009-10-28 Childrens Hosp Medical Center GTPASE INHIBITORS AND THEIR USE IN CONTROLLING PLATELET HYPERACTIVITY
US20060185492A1 (en) 2005-02-18 2006-08-24 Francois Chianese Shoulder bushing for saw blades
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US7795101B2 (en) * 2006-04-03 2010-09-14 United Microelectronics Corp. Method of forming a MOS transistor
EP1905764A1 (en) 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
KR101349187B1 (ko) * 2006-12-05 2014-01-10 (주)아모레퍼시픽 지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
AU2008311053B2 (en) * 2007-10-09 2012-08-30 Novartis Ag Pharmaceutical formulation of valsartan
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN107021951B (zh) 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
AU2011326241B2 (en) 2010-11-09 2016-11-17 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
RS63108B1 (sr) 2013-03-15 2022-04-29 Cyclerion Therapeutics Inc Sgc stimulatori
CN106304835A (zh) 2013-12-11 2017-01-04 铁木医药有限公司 sGC刺激剂
US20160324856A1 (en) 2014-01-13 2016-11-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of neuromuscular disorders
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
JP6624616B2 (ja) 2014-09-17 2019-12-25 サイクレリオン・セラピューティクス，インコーポレーテッド ｓＧＣ刺激剤
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP2019524710A (ja) 2016-07-07 2019-09-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド Ｓｇｃ刺激剤の固体形態
CA3029374A1 (en) 2016-07-07 2018-01-11 Ironwood Pharmaceuticals, Inc. Phosphorus prodrugs of sgc stimulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) * 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
AU6497701A (en) * 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
PE20020870A1 (es) * 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) * 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

Also Published As

Publication number Publication date
HUP0302845A3 (en) 2005-11-28
US20030022939A1 (en) 2003-01-30
DK1361882T3 (da) 2007-03-12
KR20030074809A (ko) 2003-09-19
AU2002253009B2 (en) 2006-09-14
US6812253B2 (en) 2004-11-02
TWI241190B (en) 2005-10-11
BG107994A (bg) 2004-08-31
RS51645B (en) 2011-10-31
IL157208A (en) 2009-09-22
HUP0302845A2 (hu) 2003-12-29
US6617359B2 (en) 2003-09-09
NO333522B1 (no) 2013-07-01
NO20033546L (no) 2003-09-24
CA2437966A1 (en) 2002-08-22
WO2002064146A1 (en) 2002-08-22
EP1361882A1 (en) 2003-11-19
EP1361882B1 (en) 2006-11-08
KR101017531B1 (ko) 2011-02-28
EE05302B1 (et) 2010-06-15
DE60215919D1 (de) 2006-12-21
PT1361882E (pt) 2007-01-31
HRP20030646A2 (en) 2005-06-30
ES2274025T3 (es) 2007-05-16
JP4317689B2 (ja) 2009-08-19
ATE344669T1 (de) 2006-11-15
SK286513B6 (sk) 2008-12-05
BG66065B1 (bg) 2011-01-31
MY135778A (en) 2008-06-30
US20050054729A1 (en) 2005-03-10
US7202278B2 (en) 2007-04-10
ZA200305412B (en) 2004-09-02
RU2308946C2 (ru) 2007-10-27
IL157208A0 (en) 2004-02-19
RU2003127750A (ru) 2005-03-10
BR0207178A (pt) 2004-03-30
CZ20032154A3 (cs) 2004-05-12
CY1106278T1 (el) 2011-10-12
PL363452A1 (en) 2004-11-15
EE200300368A (et) 2003-10-15
SI1361882T1 (sl) 2007-02-28
NZ527469A (en) 2005-04-29
JP2004518713A (ja) 2004-06-24
HK1062140A1 (en) 2004-10-21
DE60215919T2 (de) 2007-05-31
RS61703A (en) 2006-12-15
CA2437966C (en) 2011-06-14
MXPA03006841A (es) 2003-11-13
CN1496264A (zh) 2004-05-12
SK10112003A3 (sk) 2004-01-08
US20040019114A1 (en) 2004-01-29
CN100553631C (zh) 2009-10-28
PE20020884A1 (es) 2002-11-25

Similar Documents

Publication Publication Date Title
NO20033546L (no) 4-fluor-N-indan-2-yl-benzamid og dets anvendelse som legemiddel
SE0200979D0 (sv) New compounds
SE0101387D0 (sv) Novel compounds
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
NO20060416L (no) Ny anvendelse I
SE0100569D0 (sv) New compounds
NO20065904L (no) Terapeutiske forbindelser
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
CY1111543T1 (el) Νεες ενωσεις
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
PA8563801A1 (es) Esteres hidroxamato del acido n-(4-fenil sustituido)- antranilico
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
SE0102440D0 (sv) New compound
AR032553A1 (es) Derivados de alfa-amino-n-hidroxi-acetamida.
DK1664044T3 (da) Monohydreret natriumsalt af S-tenatoprazol og dets anvendelse i form af en protonpumpehæmmer
NO20033413L (no) Krystallmodifisering av et syklisk depsipeptid med forbedret aktivitet
HRPK20040328B3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
DE60300683D1 (de) Prucaloprid-n-oxid
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
SV2003001422A (es) "1,3-diarilprop-2-en-1-onas,composiciones que las contienen y su utilizacion"
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees